Expertise in
3
conditions

Hongwei Z. Xu

324 Jingwu Road, 
Jinan, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
324 Jingwu Road, 
Jinan, CN 
OverviewLocationsClinical Research

Overview

Hongwei Xu practices in Jinan, China. Xu is highly rated in 3 conditions, according to our data. Their top areas of expertise are Acute Pancreatitis, Hereditary Pancreatitis, Classical Hodgkin Lymphoma, Endoscopy, and Colonoscopy.

Their clinical research consists of co-authoring 168 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

324 Jingwu Road, Jinan, 250021, China
Other Locations
2901 Beidi Road, Minhang, 201106, China
1518 Huancheng Rd, Jiaxing, 314000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
Enrollment Status: Completed
Publish Date: July 22, 2024
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: Hemay007
Study Phase: Phase 2
View 3 Less Clinical Trials

168 Total Publications

ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer.
ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer.
Journal: Epigenomics
Published: November 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xu's expertise for a condition
ConditionClose
      View All 41 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile